Elazreg, R. (2014). FORMULATION AND IN VITRO EVALUATION OF METHAZOLAMIDE ELASTIC VESICULAR SYSTEMS. Al-Azhar Journal of Pharmaceutical Sciences, 49(1), 75-84. doi: 10.21608/ajps.2014.6958
Rania Elazreg. "FORMULATION AND IN VITRO EVALUATION OF METHAZOLAMIDE ELASTIC VESICULAR SYSTEMS". Al-Azhar Journal of Pharmaceutical Sciences, 49, 1, 2014, 75-84. doi: 10.21608/ajps.2014.6958
Elazreg, R. (2014). 'FORMULATION AND IN VITRO EVALUATION OF METHAZOLAMIDE ELASTIC VESICULAR SYSTEMS', Al-Azhar Journal of Pharmaceutical Sciences, 49(1), pp. 75-84. doi: 10.21608/ajps.2014.6958
Elazreg, R. FORMULATION AND IN VITRO EVALUATION OF METHAZOLAMIDE ELASTIC VESICULAR SYSTEMS. Al-Azhar Journal of Pharmaceutical Sciences, 2014; 49(1): 75-84. doi: 10.21608/ajps.2014.6958
FORMULATION AND IN VITRO EVALUATION OF METHAZOLAMIDE ELASTIC VESICULAR SYSTEMS
Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
Abstract
Eye is the most unique organ of the body. Various drug delivery systems are used to deliver drug into the eyes but there are various limitations of conventional systems, so various novel approaches like nanovesicular systems were used to improve ocular contact time, bioavailability, residence time and dosing frequency.Nanovesicular system with elastic properties can provide a controlled delivery of Methazolamide (MZA) which is used to treat glaucoma by inhibiting the action of carbonic anhydrase enzyme. The elastic nanovesicular carriers were formulated using Span 60 (SP 60) with one of the following edge activators (EA): Tween 80 (TW80), Tween 60 (TW 60), Brij 35 (BJ 35), and Brij 58 (BJ 58) in the ratio (90:10; 80:20; 70:30 w: w). The prepared formulae were evaluated for their sizes, entrapment efficiencies (EE %), relative deformability, and in vitro release. The results show that the selected formulae (S1, S4, S7, and S8) have the suitable particle size and EE%, thus can be used for any further investigations.
Top